Senior CMC Project Manager (Biologics)

Location: Princeton, NJ or Oxford, UK (on-site)

Summit Therapeutics, Inc. is seeking a Senior CMC Project Manager (Biologics). Ivonescimab, known as SMT112, is a novel, potential first‑in‑class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD‑1 with the anti‑angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD‑1 and VEGF. Summit has begun its clinical development of ivonescimab in non‑small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC who have progressed after treatme...